← ANALYST RATINGS · TIPRANKS
MBX Biosciences, Inc. (MBX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $101, the highest $150, the lowest $84.00. The average is +104.2% from the last price of $49.61.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $54.00 → $53.00−1.9% | Hold | +6.8% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $53.00 → $52.00−1.9% | Hold | +4.8% | Downgrade | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $53.00 → $52.00−1.9% | Hold | +4.8% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $53.00 → $52.00−1.9% | Hold | +4.8% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $52.00 → $51.00−1.9% | Hold | +2.8% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $51.00 → $53.00+3.9% | Hold | +6.8% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $88.00 | Buy | +77.4% | Reiterated | 13.10.26on TipRanks 04:50 | −5.8%next day +0.7% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $150 | Buy | +202.4% | Reiterated | 12.10.26on TipRanks 07:30 | −2.2%next day −5.8% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $70.00 → $84.00+20.0% | Buy | +69.3% | Reiterated | 12.10.26on TipRanks 07:20 | −2.2%next day −5.8% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $88.00 | Buy | +77.4% | Initiated | 21.08.26on TipRanks 06:36 | −0.4%next day +0.4% · 5 days −5.5% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $70.00 → $88.00+25.7% | Buy | +77.4% | Reiterated | 10.08.26on TipRanks 10:21 | −2.4%next day +0.1% · 5 days +3.2% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $121 | Buy | +143.9% | Assigned | 08.08.26on TipRanks Aug 6 12:50 | −0.4%next day +0.4% · 5 days −1.3% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $60.00 → $90.00+50.0% | Buy | +81.4% | Reiterated | 24.07.26on TipRanks Jul 23 21:15 | −2.6%next day −1.2% · 5 days +5.2% | ↗ |
| Unknown Analyst | Oppenheimer | $80.00 | Buy | +61.3% | Reiterated | 15.06.26on TipRanks 08:15 | +8.0%next day +3.4% · 5 days +21.6% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $76.00 → $86.00+13.2% | Buy | +73.4% | Reiterated | 12.05.26on TipRanks 05:50 | −7.6%next day +0.8% · 5 days −17.2% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 16:25 | +17.2%next day −2.4% · 5 days −21.0% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $31.97 | Sell | −35.6% | Initiated | 04.12.25on TipRanks Dec 5 02:40 | −10.1%next day +4.5% · 5 days −7.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering MBX Biosciences, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $90.43 at a price of $58.62 (+54.3%); now: $101 at $49.61 (+104.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 22 | 23 | 14 | 4 | 5 |
| Buy | 4 | 3 | 4 | 8 | 7 | 5 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.83 (from $-1.05 to $-0.69). Last quarter: $-0.78.
Best top-analyst consensus in the sector · General
About MBX Biosciences, Inc.
- CEO: Steve Hoerter
- Employees: 63
- 11711 N. Meridian Street, Carmel, IN, 46032, US
- mbxbio.com
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Data from the stock’s TipRanks forecast page, read 29 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗